Wound healing

Modern wound management can shorten treatment and turn in-patient treatment into out-patient care, reducing time and costs. It’s all down to today’s more sophisticated materials.

Photo: Wound healing

Bayer MaterialScience contributes much to the medical care with its range of polyurethane raw materials plus thermoplastics and films. For example, Bayblend M850XF, a blend of polycarbonate and acrylonitrilebutadiene-styrene, is very well suited for housings for medical equipment such as surgical instruments, diagnostic devices and drug administration systems. Like most of the firm’s thermoplastics it offers very good impact strength and rigidity. 

The company’s current developments include the Baymedix brand hydrophilic prepolymers used to manufacture polyurethane foams for medical wound dressings. The foams absorb aqueous liquids and retain them better than conventional foams. They can be combined with Platilon thermoplastic polyurethane films, which are water vapour permeable and allow wounds to breathe. Watertight films keep outside liquids and dirt from the wound. The films are produced by Epurex Films GmbH & Co. KG – a wholly owned subsidiary of Bayer MaterialScience assigned to Functional Films that also develops non-wovens, foams and adhesives for medical care applications. 

05.02.2012

Read all latest stories

Related articles

Photo

Bayer in cancer collaboration

Finnish pharma company Orion and German healthcare giant Bayer have entered into an agreement for the development and commercialisation of a novel drug targeting prostate cancer.

Photo

Move to significantly strengthen position in consumer care

Bayer has agreed to acquire the consumer care business of U.S. pharmaceutical company Merck & Co., Inc., Whitehouse Station, NJ, USA, for a purchase price of USD 14.2 billion (EUR 10.4 billion).

Photo

Bayer to Present Data on Oncology Pipeline

Bayer HealthCare announced that the company will present preclinical data that introduce investigational compounds for both therapy and imaging in its early oncology pipeline with unique and novel…